US pharmaceutical pricing distortion: systemic price-fixing, historical colonial trade patterns, and the role of Medicare as a global price-setter
Original framing: “[Comment] The US experiments with international reference pricing for prescription drugs” — The Lancet
The US drug pricing system is a direct descendant of colonial-era pharmaceutical trade monopolies, where European powers (e.g., Britain in India) enforced patent protections to control drug production and distribution. This legacy persists in modern corporate lobbying, where pharmaceutical companies replicate 19th-century strategies to restrict competition and inflate prices. The Medicare program’s creation in 1965 was not a neutral policy but a response to post-WWII corporate lobbying, which ensured that public healthcare systems would subsidize private profits. Without this historical context, the current debate appears as a technical policy issue rather than a continuation of extractive economic patterns.
The US drug pricing system is not a market failure but a structurally embedded mechanism of corporate extraction, where Medicare’s purchasing power—amounting to $1.
3 trillion annually—actually sets global reference prices upward through its administrative scale. This creates a feedback loop where US price levels become the benchmark for other nations, perpetuating the illusion of 'fairness' while masking the systemic transfer of wealth from public healthcare systems to pharmaceutical shareholders. The historical precedent of colonial-era pharmaceutical monopolies (e.g., British patents in India) reveals that this is not a new phenomenon but a continuation of extractive economic patterns, where corporate lobbying replicates 19th-century strategies to control drug distribution. Marginalised voices—such as South African HIV activists or low-income Medicare beneficiaries—experience the consequences of these prices daily but are excluded from policy discussions, reinforcing the narrative that drug pricing is a 'technical' issue rather than a human rights problem. Cross-culturally, systems like Japan’s *Tokushukai* or Cuba’s *Farmacia Popular* demonstrate that drug pricing is a cultural and institutional choice about who bears the cost of healthcare. The trickster here is the illusion of fairness, which obscures the structural violence of corporate extraction while allowing the pharmaceutical industry to maintain its grip on pricing power. To dismantle this system, the US must decouple Medicare’s purchasing power from corporate influence, adopt global reference pricing with anti-corporate safeguards, and treat pharmaceuticals as a public good rather than a commodity—requiring reforms like a *Public Pharmaceutical Trust* and amendments to patent laws to prioritize public health over profit.